Haemonetics Corporation (HAE), a global healthcare company providing blood management solutions and technologies, reported second-quarter fiscal 2027 financial results, with revenue growth across its Apheresis and MedSurg businesses. The company also raised its full-year fiscal 2027 revenue and organic growth guidance.
Company Profile
Haemonetics develops and provides products and solutions for blood and plasma collection, surgical blood management and transfusion services. Its operations are organized into Apheresis and MedSurg business segments, with offerings that include plasma collection systems, vascular closure devices and blood management technologies.
Q2 Fiscal 2027 Financial Highlights
For the quarter ended September 26, 2026, revenue increased 9.3% to $357.8 million from $327.3 million in the prior-year quarter.
GAAP earnings per share rose 23% to $1.00 from $0.81, while adjusted diluted EPS increased 6% to $1.35 from $1.27.
GAAP gross margin improved to 61.7% from 59.5%, while adjusted gross margin increased to 61.9% from 60.5%.
GAAP operating margin rose to 21.0% from 17.9%, whereas adjusted operating margin declined to 26.3% from 26.7%.
Segment Performance
Segment ope...